Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Universal Sequencing Technology Corporation has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are split between 2 distinct examiners and 2 distinct art units. This distribution means that no applications share the same examiner or the same art unit. The presence of 2 distinct art units suggests that the company's sequencing technologies are being classified into different specialized areas of biotechnology by the patent office.
The busiest examiner, SMITH, JENNIFER JOY, is responsible for 1 busiest examiner pending office action. This is a portion of the 2 pending office actions currently active. Because the 2 pending office actions are handled by 2 distinct examiners, the company's prosecution risk is diversified across different individuals. Practitioners must tailor their arguments to the specific standards of 2 distinct art units, as the 1 busiest examiner pending office action under SMITH, JENNIFER JOY may face different hurdles than the other active case. This structure highlights the varied technical nature of the company's sequencing-related patent filings across 2 distinct art units.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SMITH, JENNIFER JOY | 1 | — | — |
| WHITE, DENNIS MICHAEL | 1 | 58.0% | +48.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18376266 | METHODS AND COMPOSITIONS FOR TRACKING NUCLEIC ACID FRAGMENT ORIGIN FOR NUCLEIC ACID SEQUENCING | SMITH, JENNIFER JOY | — |
| 18299528 | LATERAL FLOW PLATFORM FOR DETECTION OF DIAGNOSTIC MARKERS | WHITE, DENNIS MICHAEL | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18299528 | LATERAL FLOW PLATFORM FOR DETECTION OF DIAGNOSTIC MARKERS | WHITE, DENNIS MICHAEL | — |
| Art Unit | Apps |
|---|---|
| 1685 | 1 |
| 1758 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18376266 | METHODS AND COMPOSITIONS FOR TRACKING NUCLEIC ACID FRAGMENT ORIGIN FOR NUCLEIC ACID SEQUENCING | SMITH, JENNIFER JOY | 1685 | §101§102 | Non-Final OA | — | Pending | Oct 03, 2023 |
| 18299528 | LATERAL FLOW PLATFORM FOR DETECTION OF DIAGNOSTIC MARKERS | WHITE, DENNIS MICHAEL | 1758 | §103§112 | Non-Final OA | — | Pending | Apr 12, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialUniversal Sequencing Technology Corporation has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Jennifer Joy Smith has the most, with 1 of Universal Sequencing Technology Corporation's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
